Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Fineline Cube Jun 16, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Fineline Cube Jun 16, 2026
Company

Novo Nordisk Reports Soaring Global Sales in 2024, Driven by Diabetes and Obesity Care

Fineline Cube Feb 6, 2025

Denmark’s Novo Nordisk (CPH: NOVO-B) reported this week that its global sales during 2024 reached...

Company Drug

Astellas Pharma Submits NDA for Avacincaptad Pegol in Japan for Geographic Atrophy

Fineline Cube Feb 6, 2025

Japan-based major Astellas Pharma (TYO: 4503) announced that it has submitted a New Drug Application...

Company Drug

Roche’s Susvimo Approved by FDA for Diabetic Macular Edema

Fineline Cube Feb 6, 2025

Swiss pharmaceutical giant Roche (SWX: ROG) announced that it has received approval from the US...

Company Drug

FDA Approves Enhertu for HER2-Low and HER2-UltraLow Breast Cancer

Fineline Cube Feb 6, 2025

The US Food and Drug Administration (FDA) has approved Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody...

Company Deals

Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study

Fineline Cube Feb 6, 2025

Nanjing-headquartered Immunophage Biotech Co., Ltd., a targeted therapy developer with operations in China, Australia, and...

Company Drug

Betta Pharmaceuticals Gains NMPA Approval for BPI-452080 Clinical Study

Fineline Cube Feb 6, 2025

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received approval from the...

Company Drug

Haisco’s HSK39004 Gains NMPA Approval for COPD Clinical Trials

Fineline Cube Feb 6, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...

Company Medical Device

Sino Medical Sciences’ NC Rockstar Catheter Gains MDA Approval in Malaysia

Fineline Cube Feb 6, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...

Company Deals

Henan Lingrui to Acquire Yingu Pharma for RMB 704 Million

Fineline Cube Feb 6, 2025

China’s Henan Lingrui Pharmaceutical Co., Ltd. (SHA: 600285) announced plans to acquire a 90% ownership...

Company Drug

Junshi Biosciences Receives NMPA Approval for JS213 Clinical Trials

Fineline Cube Feb 6, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...

Company Drug

Beijing Biostar’s Utidelone Gains FDA Approval for Global Phase II/III Study

Fineline Cube Feb 6, 2025

China’s Beijing Biostar Technologies Ltd (HKG: 2563) announced that it has received approval from the...

Company Deals

ClouDr Group Integrates DeepSeeker R1 into CloudrBrain to Boost Chronic Disease Management

Fineline Cube Feb 6, 2025

China-based ClouDr Group Limited (HKG: 9955) announced the integration of the DeepSeeker R1 model into...

Company

Henlius’ Serplulimab Receives EU Approval for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Feb 6, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received marketing approval from...

Company Drug

Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378

Fineline Cube Feb 6, 2025

China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National...

Company Deals

Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms

Fineline Cube Feb 5, 2025

China-based Tofflon Science and Technology Group Co., Ltd. (SHE: 300171), a total solution service provider...

Company Deals

Becton Dickinson Considers Spinning Off Life Sciences Division

Fineline Cube Feb 5, 2025

US-based Becton, Dickinson and Co. (BD) is reportedly considering spinning off its life sciences division,...

Company Deals

Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition

Fineline Cube Feb 5, 2025

Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone...

Company Deals

Nona Biosciences Partners with Invetx for Animal Health Therapies

Fineline Cube Feb 5, 2025

Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership...

Company

AbbVie Reports Strong Q4 and Full-Year 2024 Financials

Fineline Cube Feb 5, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) has released its Q4 and full-year 2024 financial results,...

Company Drug

IASO Bio’s CAR-T Therapy Fucaso Accepted for Review in Singapore

Fineline Cube Feb 5, 2025

China-based IASO Biotherapeutics has announced that a New Drug Application (NDA) for its BCMA-targeted chimeric...

Posts pagination

1 … 237 238 239 … 684

Recent updates

  • NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)
  • China’s CDE Proposes Framework for Reference Listed Drug Selection Following Marketing Authorization Holder Changes for Foreign-Originator Drugs Manufactured Locally
  • China’s National Health Commission Revises Physician Practice Regulations to Align with Physicians Law and Enhance Multi-Site Practice Framework
  • Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders
  • Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Policy / Regulatory

China’s CDE Proposes Framework for Reference Listed Drug Selection Following Marketing Authorization Holder Changes for Foreign-Originator Drugs Manufactured Locally

Policy / Regulatory

China’s National Health Commission Revises Physician Practice Regulations to Align with Physicians Law and Enhance Multi-Site Practice Framework

Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.